Charles Link
Company: Syncromune
Job title: Executive Chairman
Seminars:
Utilizing Personalized SYNC-T Therapy in situ Vaccination & Intramural Infusion to Induce Systemic Responses in Patients with Metastatic Castrate-Resistant Prostate Cancer 3:30 pm
Targeting metastatic castrate-resistant prostate cancer (mCRPC) to improve response to immunotherapy Showcasing the personalized in-situ tumor vaccine from device-induced partial cryolysis of a targeted solid tumor Combining in-situ vaccine with immediate intratumoral infusion of a multi-target proprietary drug candidate SV-102 to induce a systemic immune responseRead more
day: Conference Day Two